INDICATION

EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, 200 mg/50 mg tablets; 200 mg/50 mg, 150 mg/37.5 mg oral pellets) is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1-6 infection without cirrhosis or with compensated cirrhosis.

PATIENT SUPPORT MATERIALS

Thumbnail of EPCLUSA education line resource card

Education line resource card

A card with information about the EPCLUSA Education Line, including the contact number and a list of offerings.